Atea Pharmaceuticals, Inc.
AVIR
$5.27
-$0.41-7.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -12.99% | 45.09% | 125.03% | 88.41% | 39.40% |
| Gross Profit | 12.99% | -45.09% | -125.03% | -88.41% | -39.40% |
| SG&A Expenses | -23.38% | -27.31% | -46.72% | -34.62% | -25.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.27% | 26.98% | 58.56% | 45.05% | 16.92% |
| Operating Income | 15.27% | -26.98% | -58.56% | -45.05% | -16.92% |
| Income Before Tax | 10.95% | -33.23% | -54.98% | -35.34% | 8.25% |
| Income Tax Expenses | -88.41% | -75.37% | -3,108.00% | -13.27% | -14.81% |
| Earnings from Continuing Operations | 11.38% | -32.59% | -33.76% | -34.98% | 8.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.38% | -32.59% | -33.76% | -34.98% | 8.29% |
| EBIT | 15.27% | -26.98% | -58.56% | -45.05% | -16.92% |
| EBITDA | 15.31% | -27.06% | -58.74% | -45.20% | -16.97% |
| EPS Basic | 7.28% | -42.59% | -44.62% | -44.15% | 7.75% |
| Normalized Basic EPS | 7.05% | -48.63% | -93.01% | -77.90% | -29.40% |
| EPS Diluted | 7.28% | -42.59% | -44.62% | -44.15% | 7.75% |
| Normalized Diluted EPS | 7.05% | -48.63% | -93.01% | -77.90% | -29.40% |
| Average Basic Shares Outstanding | -4.41% | -7.00% | -7.50% | -6.36% | -0.60% |
| Average Diluted Shares Outstanding | -4.41% | -7.00% | -7.50% | -6.36% | -0.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |